-
1 Comment
Orphazyme A/S is currently in a long term downtrend where the price is trading 30.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Finally, its free cash flow fell by 109.8% to $-168M since the same quarter in the previous year.
Based on the above factors, Orphazyme A/S gets an overall score of 1/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | F |
CurrencyCode | EUR |
ISIN | DK0060910917 |
PE Ratio | None |
---|---|
Target Price | None |
Market Cap | 3K |
Dividend Yield | 0.0% |
Beta | 0.11 |
Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1TB.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025